Recent articles
Here's Why Arrowhead Pharmaceuticals Stock Soared 410% in 2019
The RNAi drug developer tickled investors with promising clinical data.
Why Alnylam Pharmaceuticals Rose 57.9% in 2019
All of the share price gains came after September -- and for good reason.
2 Small-Cap Stocks With Big-Cap Potential
These two small-cap biopharmas have promising early-stage drug candidates that could take them far if all goes according to plan.
Here's Why Intra-Cellular Therapies Is Sinking Today
The pharmaceutical company announced the pricing of a public stock offering. It's wisely taking advantage of a soaring stock price to raise cash ahead of a crucial market launch.
Here's Why Matinas BioPharma Shares Lost as Much as 16.9% Today
The small-cap pharma sank on an update from its top competitor.
Here's Why Apellis Pharmaceuticals Stock Jumped as Much as 40.7% Today
The company's lead drug candidate bested a competitor's therapy on a key endpoint in a phase 3 trial.
2 Growth Stocks for In-the-Know Investors
These genetic testing stocks took divergent paths in the final months of 2019, but they're solid options for investors with a long-term mindset.
Here's Why Sage Therapeutics Lost 53.3% in December
An important drug candidate failed to meet its primary endpoint in a clinical trial. That left the door open for a new competitor.
Here's Why TG Therapeutics Jumped 35.5% in December
Two triple-combination therapies delivered impressive results in early-stage studies, which propelled the stock to a 170% gain in 2019.
Here's Why 10x Genomics Rose 17.5% in December
The company scored an important win in a patent dispute.
2 Great Stocks for Low-Risk Investors
These two businesses generate strong cash flow, pay dividends, and have a strong track record of beating the S&P 500.
Can Renewable Energy Group Afford Share Buybacks?
An extended and reinstated tax credit will create a more than $500 million windfall for the renewable fuels leader in early 2020, but the future beckons.
Here's Why Exact Sciences Gained 14.1% in December
Impressive long-term study results for an important product eased investor concerns over the tie-up between Exact Sciences and Genomic Health.
Here's Why Deciphera Pharmaceuticals Rose 31.6% in December
The solid end of the year performance meant shares nearly tripled in 2019.
Here's Why Iovance Biotherapeutics Jumped 21.2% in December
The biopharma stock more than tripled in 2019.
Here's Why Bristol-Myers Squibb Jumped 12.7% in December
Investors breathed a sign of relief as multiple pipeline assets from Celgene closed the year with positive updates.
These 2 Stocks Will Rise After the New Year
The next decade will require a lot of what these two renewable energy companies offer, but investors likely won't have to wait very long.
Here's Why Incyte Fell as Much as 12.6% Today
An important clinical trial failed, reminding investors of the company's poor track record with its pipeline.
These 2 Stocks Will Fall After the New Year
These two promising RNAi drug developers are trading at hefty premiums going into 2020.
Here's Why Sol-Gel Technologies Stock Is Soaring Today
The small-cap company announced promising results from a clinical trial.